Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Stock Information for EMCORE Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About EMCORE Corporation

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Kalaris Appoints Laurie Keating to Board of Directors
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris to Present at Clinical Trials at the Summit 2026
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.